Snapshot from Aug 15, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / Capricor Securities Fraud Class Action
Regulatory Securities Fraud

Capricor Securities Fraud Class Action

Analysis based on 38 articles · First reported Jul 30, 2026 · Last updated Aug 14, 2026

Sentiment
-60
Attention
4
Articles
38
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The revelation of undisclosed SAP changes and the FDA's negative assessment of the HOPE-3 trial results caused a 64% drop in Capricor's stock price, erasing significant market value. The securities class action and ongoing investigations may lead to substantial legal costs and potential settlements, further impacting the company's financial position and investor confidence.

Biotechnology Pharmaceuticals Legal Services
Event Summary

Paragon Therapeutics, a biotechnology company developing Deramiocel for Duchenne muscular dystrophy, faces a securities fraud class action lawsuit. The lawsuit alleges that the company and certain officers made false and misleading statements regarding the clinical trial data and regulatory pathway for Deramiocel. Specifically, the FDA's July 27, 2026 briefing document revealed that Capricor made changes to the pre-specified statistical analysis plan (SAP) without prior FDA agreement, and that the HOPE-3 trial did not meet its pre-specified primary and secondary efficacy endpoints. This disclosure caused Capricor's stock to plummet 64% to $7 per share. Multiple law firms, including Hagens Berman, Bronstein, Gewirtz & Grossman, LLC, and Kaplan Fox & Kilsheimer, have filed or announced investigations and class actions on behalf of investors who purchased Capricor securities between December 17, 2025 and July 26, 2026. The lead plaintiff deadline is September 28, 2026.

Key Actions
100 United States — Food and Drug Administration released briefing documents Paragon Therapeutics
97 Bronstein, Gewirtz & Grossman, LLC filed class action Paragon Therapeutics
94 Paragon Therapeutics announced advisory meeting United States — Food and Drug Administration
92 Bleichmar Fonti & Auld LLP announced investigation Paragon Therapeutics
90 Paragon Therapeutics announced positive trial results
89 Paragon Therapeutics provided misleading statements
88 Kaplan Fox & Kilsheimer filed class action Paragon Therapeutics
79 Paragon Therapeutics launched public offering
78 Hagens Berman filed class action lawsuit Paragon Therapeutics
Entities Involved
priv
Paragon Therapeutics
Capricor is the defendant in the securities fraud class action. The alleged misrepresentations regarding Deramiocel's clinical data and regulatory pathway led to a 64% stock price collapse and legal exposure.
Importance 100.0 Sentiment -80.0
govactor
United States — Food and Drug Administration
The FDA's briefing document revealed discrepancies in Capricor's trial analysis, triggering the stock crash and subsequent litigation. The FDA's regulatory decision on Deramiocel's BLA remains pending.
Importance 90.0 Sentiment 0.0
priv
Hagens Berman
Hagens Berman opened an investigation and filed a class action lawsuit against Capricor, representing investors who suffered losses. The firm is actively seeking lead plaintiff and whistleblower information.
Importance 70.0 Sentiment 0.0
priv
Kaplan Fox & Kilsheimer
Kaplan Fox & Kilsheimer filed a class action lawsuit against Capricor and is reminding investors of the lead plaintiff deadline. The firm has a history of significant securities litigation recoveries.
Importance 60.0 Sentiment 0.0
priv
Bronstein, Gewirtz & Grossman, LLC
Bronstein, Gewirtz & Grossman, LLC announced the class action lawsuit and is encouraging investors to join. The firm is representing investors on a contingency fee basis.
Importance 60.0 Sentiment 0.0
per
Reed Kathrein
Reed Kathrein is the Hagens Berman partner leading the investigation into Capricor. He is the contact for investors and whistleblowers.
Importance 40.0 Sentiment 0.0
govactor
United States — United States Securities and Exchange Commission
The SEC is mentioned in relation to its whistleblower program, which may provide rewards for information about Capricor's alleged misconduct. The SEC is not a direct party in the class action.
Importance 30.0 Sentiment 0.0
per
Peretz Bronstein
Peretz Bronstein is the founding partner of Bronstein, Gewirtz & Grossman, LLC, which is representing investors in the class action. He is a contact for the firm.
Importance 30.0 Sentiment 0.0
per
Nathan Miller
Nathan Miller is the Client Relations Manager at Bronstein, Gewirtz & Grossman, LLC, serving as a contact for investors.
Importance 20.0 Sentiment 0.0
per
Jeffrey P. Campisi
Jeffrey P. Campisi is a partner at Kaplan Fox & Kilsheimer, serving as a contact for investors in the class action.
Importance 20.0 Sentiment 0.0
per
Laurence D. King
Laurence D. King is a partner at Kaplan Fox & Kilsheimer, serving as a contact for investors in the class action.
Importance 20.0 Sentiment 0.0
Relationships
Paragon Therapeutics related ↔ United States — Food and Drug Administration
Paragon Therapeutics related ↔ United States — United States Securities and Exchange Commission
United States — Food and Drug Administration related ↔ Hagens Berman
United States — Food and Drug Administration related ↔ Kaplan Fox & Kilsheimer
United States — Food and Drug Administration related ↔ Bronstein, Gewirtz & Grossman, LLC
United States — Food and Drug Administration related ↔ Reed Kathrein
United States — Food and Drug Administration related ↔ United States — United States Securities and Exchange Commission
United States — Food and Drug Administration related ↔ Peretz Bronstein
United States — Food and Drug Administration related ↔ Nathan Miller
Hagens Berman related ↔ Kaplan Fox & Kilsheimer
Hagens Berman related ↔ Bronstein, Gewirtz & Grossman, LLC
Hagens Berman related ↔ Reed Kathrein
Hagens Berman related ↔ United States — United States Securities and Exchange Commission
Hagens Berman related ↔ Peretz Bronstein
Hagens Berman related ↔ Nathan Miller
+ 15 more relationships View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.